Clinical efficacy observation of 577 nm subthreshold micropulse Laser combined with anti—VEGF drugs in treatment of refractory diabetic macular edema

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068324

Enrollment

Unknown

Registered

2023-02-15

Start date

2023-02-13

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory diabetic macular edema

Interventions

Control group:Intravitreal injection of anti-VEGF drugs

Research group:Intravitreal injection of anti-VEGF drugs combine with macular 577 nm micropulse laser

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.patients with refractory DME as defined by investigators,and and completed panretinal laser photocoagulation without macular grid laser; 2.Age from 30 to 80 years; 3.Patients informed consent.

Exclusion criteria

Exclusion criteria: 1.Macular edema caused by retinal vein occlusion, recurrent uveitis, vitreous macular traction, frustration trauma, high myopia and other factors; 2.Patients with abnormal intraocular pressure, abnormal fixation function, unclear refractive media or infectious ophthalmic diseases; 3.Surgical contraindications such as hypertension or liver and kidney function, coagulation dysfunction, mental abnormalities; 4,Pregnant or lactating women. 5.Poor compliance, change of treatment plan or follow-up time.

Design outcomes

Primary

Measure	Time frame
Central Macular Thickness;Best corrected visual acuity;Retinal sensitivity;Subretinal fluid;	—

Secondary

Measure	Time frame
Occurrence of adverse events;Occurrence of adverse events;	—

Countries

China

Contacts

Public ContactZhang Jinglin

Guangzhou Aier Eye Hospital

26020926@qq.com13560091515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026